AKBA Q4 2024 Earnings — Akebia Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena

AKBAAkebia Therapeutics, Inc.

$365M

Q4 2024 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$46M-17.3% YoY

Gross Profit

$26M56.2% margin

Operating Income

-$14M-30.8% margin

Net Income

-$23M-49.0% margin

EPS (Diluted)

$-0.10

QoQ Revenue Growth

+24.2%

Cash Flow

Operating Cash Flow

-$4M

Free Cash Flow

-$4M

Stock-Based Comp.

$0

Balance Sheet

Total Assets

$221M

Total Liabilities

$270M

Stockholders' Equity

-$49M

Cash & Equivalents

$52M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$46M	$56M	-17.3%
Gross Profit	$26M	$38M	-30.4%
Operating Income	-$14M	$1M	-1141.3%
Net Income	-$23M	$614,000	-3814.0%

Revenue Segments

Product

$86M95%

License Collaboration And Other Revenue

$5M5%